<p>Progyny, Inc. ((PGNY)) 已召開其第一季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Progyny 最近的財報電話會議傳達了明顯的積極基調，管理層強調了創紀錄的第一季度收入、擴大的利潤率和強勁的現金生成，同時完成了股份回購。儘管承認存在行政清理工作、更高的資本支出和來自轉型客户的可比性噪音，管理層將這些視為可控的逆風，背景是需求的韌性和臨牀結果的驗證。</p>
<h2>創紀錄的第一季度收入和利潤超預期</h2>
<p>Progyny 報告的第一季度收入達到了指導範圍的高端，儘管同比增長僅為 1.4%，但仍顯示出強勁的需求。排除一位處於轉型護理協議下的大客户，收入增長超過 12%，淨收入、每股收益和調整後的 EBITDA 均超出管理層的指導範圍。</p>
<h2>上調全年盈利目標</h2>
<p>公司上調了調整後 EBITDA、淨收入和每股收益的全年指導，表明對盈利持久性的信心，即使在持續投資的情況下。管理層現在預計調整後 EBITDA 在 2.32 億至 2.44 億美元之間，淨收入在 1.037 億至 1.123 億美元之間，稀釋每股收益在 1.23 至 1.34 美元之間，調整後的每股收益指導為 1.98 至 2.09 美元。</p>
<h2>收入展望受轉型逆風影響</h2>
<p>對於第二季度，Progyny 指導收入範圍為 3.42 億至 3.55 億美元，意味着報告增長為 2.7% 至 6.6%，但在調整 1720 萬美元的轉型客户後，增速為 8.3% 至 12.4%。全年收入預計在 13.65 億至 14.05 億美元之間，轉化為 5.9% 至 9.0% 的增長，或在剔除轉型收入後為 10.1% 至 13.3%。</p>
<h2>健康的利用率和會員參與度</h2>
<p>管理層強調，會員參與度保持強勁，利用率趨向於公司歷史範圍的高端。公司保持全年利用率假設不變，預計在 1.04% 至 1.05% 之間，並維持每位女性獨特的 ART 週期消費在 0.93 至 0.95 之間，表明基礎活動沒有明顯放緩。</p>
<h2>利潤率擴張和韌性盈利能力</h2>
<p>毛利率在本季度有所擴大，調整後的 EBITDA 利潤率保持在健康水平，即使 Progyny 加大了對其平台和服務的投資。高管指出，運營效率和較低的股票薪酬是利潤率提升的關鍵因素，並表示這些好處預計將持續並支持持續盈利能力。</p>
<h2>強勁的現金生成和無債務資產負債表</h2>
<p>公司繼續將盈利轉化為現金，在過去一段時間內產生了約 4.46 億美元的經營現金流，並強調了強大的營運資金管理。Progyny 在季度末擁有 2.25 億美元的現金、現金等價物和可交易證券，總營運資金為 2.66 億美元，未動用的 2 億美元循環信貸額度，且資產負債表上沒有債務。</p>
<h2>完成股份回購和資本回報策略</h2>
<p>Progyny 通過在本季度回購超過 550 萬股，花費約 1.16 億美元，積極進行資本回報，完成了 2 億美元的授權。總共約 880 萬股被註銷，董事會現在正在評估潛在的新回購計劃，表明繼續願意將多餘資本返還給股東。</p>
<h2>銷售管道勢頭和降低風險的續約</h2>
<p>銷售管道和早期客户承諾的進展遠超去年，強化了公司到 2026 年的增長前景。Progyny 最大客户的一些早期積極續約決定將續約風險降低到本週期的最低水平，額外的勢頭來自渠道合作伙伴和支持 Progyny Select 產品的聚合商。</p>
<h2>第三方研究驗證臨牀和成本效益</h2>
<p>一項大型客户的長期分析顯示，Progyny 的項目提供了更多與生育相關的懷孕，治療的懷孕有效性翻倍，並在八年內減少了多胎和流產。研究還發現，早產率減少了一半以上，平均每個嬰兒的成本和 NICU 費用下降，進一步強化了 Progyny 對僱主和會員的價值主張。</p>
<h2>轉型客户影響頭條比較</h2>
<p>管理層提醒投資者，處於轉型護理安排下的一位大型前客户（將於 2025 年中期結束）正在造成同比比較中的噪音，並抑制報告增長。第一季度的 1.4% 收入增長在排除該客户後超過 12%，強調頭條放緩反映的是可比性效應，而非核心需求的減弱。</p>
<h2>增加資本支出和持續投資壓力</h2>
<p>Progyny 正在故意提升其投資水平，第一季度資本支出達到 630 萬美元，比去年增加 350 萬美元，因為它正在構建新的平台能力和會員功能。這些投資對短期自由現金的部署產生了適度壓力，但被視為維持競爭差異化和長期增長的關鍵。</p>
<h2>行政調整和資格補救</h2>
<p>公司承認，過去的行政資格調整在被覆蓋的生命數量上造成了意外，增加了報告結果的變動性。為了解決這個問題，Progyny 正在努力在年底之前從大多數客户那裏獲取完整的資格文件，旨在減少運營噪音並隨着時間的推移提高預測準確性。</p>
<h2>對潛在參與變動的保守態度</h2>
<p>儘管參與度和利用率仍然強勁，但管理層故意在歷史範圍的低端維持保守假設，以應對未來潛在的變動。這種謹慎的姿態旨在緩衝成員活動和治療模式的意外變化，否則可能會對結果造成壓力。</p>
<h2>投資者認知與估值壓力</h2>
<p>高管指出，一些投資者正在考慮可能的需求變化和更廣泛的擔憂，如與人工智能相關的勞動力市場變化，儘管這些壓力在當前運營中並不明顯。這種基本面與情緒之間的差距已成為估值壓力，管理層強調持續的執行是縮小這種脱節的主要工具。</p>
<h2>Progyny Select 的延遲收入</h2>
<p>Progyny Select 繼續受到聚合商和渠道合作伙伴的積極接納和關注，支持其作為增長向量的角色。然而，公司警告稱，由於小型僱主的標準採購和續約週期，該產品的收入貢獻將在年內後期偏向，限制了其對報告的頂線增長的短期影響。</p>
<h2>指導要點與前景</h2>
<p>展望未來，Progyny 預計第二季度收入為 3.42 億至 3.55 億美元，調整後的 EBITDA 為 5800 萬至 6200 萬美元，淨收入為 2580 萬至 2870 萬美元，GAAP 每股收益為 0.31 至 0.35 美元。對於全年，管理層的目標是收入為 13.65 億至 14.05 億美元，調整後的 EBITDA 為 2.32 億至 2.44 億美元，GAAP 每股收益在 1.23 至 1.34 美元之間，同時假設利用率指標穩定和 ART 週期消費平穩。</p>
<p>Progyny 的財報電話會議描繪了一幅公司在投資與紀律之間取得平衡的圖景，強勁的利潤率、現金流和健康的資產負債表抵消了與過渡相關的表面噪音和行政清理工作。隨着盈利指導的上調、強勁的項目活動以及對其臨牀和成本優勢的獨立驗證，該公司正將自己定位為生育福利領域的持久增長故事，即使它承認並計劃應對參與度和投資者情緒的潛在波動。</p>

PGNY

<p>Progyny, Inc. 報告了創紀錄的第一季度收入，超出預期，同比增長 1.4%，並提高了全年盈利目標。調整後的 EBITDA 預計在 2.32 億至 2.44 億美元之間，淨收入和每股收益也有所增加。公司強調了強勁的會員參與度和現金生成能力，季度末無債務，現金餘額為 2.25 億美元。Progyny 完成了 2 億美元的股票回購，並正在評估新的回購計劃。儘管受到過渡客户的影響，銷售管道顯示出積極的勢頭，第三方研究驗證了 Progyny 方案的有效性</p>

<p>Progyny, Inc. ((PGNY)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Progyny, Inc. ((PGNY)) 已召開其第一季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Progyny’s latest earnings call struck a decidedly constructive tone as management highlighted record first-quarter revenue, expanded margins, and strong cash generation alongside a fully executed share buyback. While acknowledging administrative clean‑up work, higher CapEx, and comparability noise from a transition client, executives framed these as manageable headwinds against a backdrop of resilient demand and validated clinical outcomes.</p>
<div class="lb-trans"><p>Progyny 最近的財報電話會議傳達了明顯的積極基調，管理層強調了創紀錄的第一季度收入、擴大的利潤率和強勁的現金生成，同時完成了股份回購。儘管承認存在行政清理工作、更高的資本支出和來自轉型客户的可比性噪音，管理層將這些視為可控的逆風，背景是需求的韌性和臨牀結果的驗證。</p>
</div><h2>Record Q1 Revenue and Profit Beat</h2>
<div class="lb-trans"><h2>創紀錄的第一季度收入和利潤超預期</h2>
</div><p>Progyny reported record first-quarter revenue at the high end of guidance, underscoring solid demand despite modest headline growth of 1.4% year over year. Excluding a large client under a transition-of-care agreement, revenue grew more than 12%, and net income, EPS, and adjusted EBITDA all exceeded management’s guidance ranges.</p>
<div class="lb-trans"><p>Progyny 報告的第一季度收入達到了指導範圍的高端，儘管同比增長僅為 1.4%，但仍顯示出強勁的需求。排除一位處於轉型護理協議下的大客户，收入增長超過 12%，淨收入、每股收益和調整後的 EBITDA 均超出管理層的指導範圍。</p>
</div><h2>Raised Full-Year Profitability Targets</h2>
<div class="lb-trans"><h2>上調全年盈利目標</h2>
</div><p>The company raised full-year guidance for adjusted EBITDA, net income, and EPS, signaling confidence in earnings durability even as it continues to invest. Management now expects adjusted EBITDA between $232 million and $244 million, net income of $103.7 million to $112.3 million, and diluted EPS of $1.23 to $1.34, with adjusted EPS guided to $1.98 to $2.09.</p>
<div class="lb-trans"><p>公司上調了調整後 EBITDA、淨收入和每股收益的全年指導，表明對盈利持久性的信心，即使在持續投資的情況下。管理層現在預計調整後 EBITDA 在 2.32 億至 2.44 億美元之間，淨收入在 1.037 億至 1.123 億美元之間，稀釋每股收益在 1.23 至 1.34 美元之間，調整後的每股收益指導為 1.98 至 2.09 美元。</p>
</div><h2>Revenue Outlook Masked by Transition Headwinds</h2>
<div class="lb-trans"><h2>收入展望受轉型逆風影響</h2>
</div><p>For the second quarter, Progyny guided revenue to a range of $342 million to $355 million, implying reported growth of 2.7% to 6.6% but a faster 8.3% to 12.4% pace when adjusting for the $17.2 million transition client. Full-year revenue is projected between $1.365 billion and $1.405 billion, translating to 5.9% to 9.0% growth, or 10.1% to 13.3% once transition revenue is stripped out.</p>
<div class="lb-trans"><p>對於第二季度，Progyny 指導收入範圍為 3.42 億至 3.55 億美元，意味着報告增長為 2.7% 至 6.6%，但在調整 1720 萬美元的轉型客户後，增速為 8.3% 至 12.4%。全年收入預計在 13.65 億至 14.05 億美元之間，轉化為 5.9% 至 9.0% 的增長，或在剔除轉型收入後為 10.1% 至 13.3%。</p>
</div><h2>Healthy Utilization and Member Engagement</h2>
<div class="lb-trans"><h2>健康的利用率和會員參與度</h2>
</div><p>Management emphasized that member engagement remained robust, with utilization trending toward the high end of the firm’s historical range. The company kept its full-year utilization assumptions intact at 1.04% to 1.05% and maintained expected ART cycle consumption per female unique between 0.93 and 0.95, suggesting no evident slowdown in underlying activity.</p>
<div class="lb-trans"><p>管理層強調，會員參與度保持強勁，利用率趨向於公司歷史範圍的高端。公司保持全年利用率假設不變，預計在 1.04% 至 1.05% 之間，並維持每位女性獨特的 ART 週期消費在 0.93 至 0.95 之間，表明基礎活動沒有明顯放緩。</p>
</div><h2>Margin Expansion and Resilient Profitability</h2>
<div class="lb-trans"><h2>利潤率擴張和韌性盈利能力</h2>
</div><p>Gross margin expanded in the quarter, and adjusted EBITDA margin held at healthy levels even as Progyny stepped up investments in its platform and services. Executives cited operational efficiencies and lower stock-based compensation as key contributors to margin gains, noting that these benefits are expected to recur and support ongoing profitability.</p>
<div class="lb-trans"><p>毛利率在本季度有所擴大，調整後的 EBITDA 利潤率保持在健康水平，即使 Progyny 加大了對其平台和服務的投資。高管指出，運營效率和較低的股票薪酬是利潤率提升的關鍵因素，並表示這些好處預計將持續並支持持續盈利能力。</p>
</div><h2>Robust Cash Generation and Debt-Free Balance Sheet</h2>
<div class="lb-trans"><h2>強勁的現金生成和無債務資產負債表</h2>
</div><p>The company continued to convert earnings into cash, generating roughly $446 million in operating cash flow over the trailing period and highlighting strong working capital discipline. Progyny ended the quarter with $225 million in cash, cash equivalents, and marketable securities, total working capital of $266 million, an undrawn $200 million revolver, and no debt on the balance sheet.</p>
<div class="lb-trans"><p>公司繼續將盈利轉化為現金，在過去一段時間內產生了約 4.46 億美元的經營現金流，並強調了強大的營運資金管理。Progyny 在季度末擁有 2.25 億美元的現金、現金等價物和可交易證券，總營運資金為 2.66 億美元，未動用的 2 億美元循環信貸額度，且資產負債表上沒有債務。</p>
</div><h2>Completed Share Buyback and Capital Return Strategy</h2>
<div class="lb-trans"><h2>完成股份回購和資本回報策略</h2>
</div><p>Progyny leaned into capital returns by repurchasing more than 5.5 million shares for about $116 million during the quarter, completing its $200 million authorization. In total, around 8.8 million shares were retired, and the board is now evaluating a potential new repurchase program, signaling continued willingness to return excess capital to shareholders.</p>
<div class="lb-trans"><p>Progyny 通過在本季度回購超過 550 萬股，花費約 1.16 億美元，積極進行資本回報，完成了 2 億美元的授權。總共約 880 萬股被註銷，董事會現在正在評估潛在的新回購計劃，表明繼續願意將多餘資本返還給股東。</p>
</div><h2>Sales Pipeline Momentum and De-Risked Renewals</h2>
<div class="lb-trans"><h2>銷售管道勢頭和降低風險的續約</h2>
</div><p>The sales pipeline and early client commitments are tracking substantially ahead of last year, reinforcing the company’s growth runway into 2026. Early positive renewal decisions from some of Progyny’s largest clients have reduced renewal risk to its lowest level at this point in the cycle, with additional momentum coming from channel partnerships and aggregators supporting the Progyny Select offering.</p>
<div class="lb-trans"><p>銷售管道和早期客户承諾的進展遠超去年，強化了公司到 2026 年的增長前景。Progyny 最大客户的一些早期積極續約決定將續約風險降低到本週期的最低水平，額外的勢頭來自渠道合作伙伴和支持 Progyny Select 產品的聚合商。</p>
</div><h2>Third-Party Study Validates Clinical and Cost Benefits</h2>
<div class="lb-trans"><h2>第三方研究驗證臨牀和成本效益</h2>
</div><p>A long-term analysis by a large client showed that Progyny’s programs delivered more fertility-related pregnancies, doubled pregnancy effectiveness per treatment, and reduced multiple births and miscarriages over an eight-year period. The study also found that preterm delivery rates were more than halved and that average cost per baby and NICU expenses declined, reinforcing Progyny’s value proposition for both employers and members.</p>
<div class="lb-trans"><p>一項大型客户的長期分析顯示，Progyny 的項目提供了更多與生育相關的懷孕，治療的懷孕有效性翻倍，並在八年內減少了多胎和流產。研究還發現，早產率減少了一半以上，平均每個嬰兒的成本和 NICU 費用下降，進一步強化了 Progyny 對僱主和會員的價值主張。</p>
</div><h2>Transition Client Skews Headline Comparisons</h2>
<div class="lb-trans"><h2>轉型客户影響頭條比較</h2>
</div><p>Management reminded investors that a large former client under a transition-of-care arrangement, ending mid-2025, is creating noise in year-over-year comparisons and muting reported growth. The first quarter’s modest 1.4% revenue gain becomes more than 12% when that client is excluded, underscoring that the headline slowdown reflects comparability effects rather than weakening core demand.</p>
<div class="lb-trans"><p>管理層提醒投資者，處於轉型護理安排下的一位大型前客户（將於 2025 年中期結束）正在造成同比比較中的噪音，並抑制報告增長。第一季度的 1.4% 收入增長在排除該客户後超過 12%，強調頭條放緩反映的是可比性效應，而非核心需求的減弱。</p>
</div><h2>Increased CapEx and Ongoing Investment Pressure</h2>
<div class="lb-trans"><h2>增加資本支出和持續投資壓力</h2>
</div><p>Progyny is deliberately lifting its investment profile, with first-quarter capital expenditures reaching $6.3 million, up $3.5 million from a year earlier, as it builds new platform capabilities and member features. These investments weigh modestly on near-term free cash deployment but are framed as critical to sustaining competitive differentiation and long-term growth.</p>
<div class="lb-trans"><p>Progyny 正在故意提升其投資水平，第一季度資本支出達到 630 萬美元，比去年增加 350 萬美元，因為它正在構建新的平台能力和會員功能。這些投資對短期自由現金的部署產生了適度壓力，但被視為維持競爭差異化和長期增長的關鍵。</p>
</div><h2>Administrative True-Ups and Eligibility Remediation</h2>
<div class="lb-trans"><h2>行政調整和資格補救</h2>
</div><p>The company acknowledged that past administrative eligibility true-ups had created surprises in the number of covered lives, adding variability to reported results. To address this, Progyny is working to secure full eligibility files from a majority of clients by year-end, aiming to reduce operational noise and improve forecasting accuracy over time.</p>
<div class="lb-trans"><p>公司承認，過去的行政資格調整在被覆蓋的生命數量上造成了意外，增加了報告結果的變動性。為了解決這個問題，Progyny 正在努力在年底之前從大多數客户那裏獲取完整的資格文件，旨在減少運營噪音並隨着時間的推移提高預測準確性。</p>
</div><h2>Conservative Stance on Potential Engagement Variability</h2>
<div class="lb-trans"><h2>對潛在參與變動的保守態度</h2>
</div><p>Although engagement and utilization remain strong, management is deliberately maintaining conservative assumptions at the low end of historical ranges to account for potential future variability. This cautious posture is designed to buffer against unexpected shifts in member activity and treatment patterns that could otherwise pressure results.</p>
<div class="lb-trans"><p>儘管參與度和利用率仍然強勁，但管理層故意在歷史範圍的低端維持保守假設，以應對未來潛在的變動。這種謹慎的姿態旨在緩衝成員活動和治療模式的意外變化，否則可能會對結果造成壓力。</p>
</div><h2>Investor Perception and Valuation Overhangs</h2>
<div class="lb-trans"><h2>投資者認知與估值壓力</h2>
</div><p>Executives noted that some investors are pricing in headline risks around possible demand shifts and broader concerns such as AI-related labor market changes, even though these pressures are not evident in current operations. This gap between fundamentals and sentiment has become a valuation overhang, with management emphasizing ongoing execution as the primary tool to narrow that disconnect.</p>
<div class="lb-trans"><p>高管指出，一些投資者正在考慮可能的需求變化和更廣泛的擔憂，如與人工智能相關的勞動力市場變化，儘管這些壓力在當前運營中並不明顯。這種基本面與情緒之間的差距已成為估值壓力，管理層強調持續的執行是縮小這種脱節的主要工具。</p>
</div><h2>Delayed Revenue from Progyny Select</h2>
<div class="lb-trans"><h2>Progyny Select 的延遲收入</h2>
</div><p>Progyny Select continues to see favorable reception and interest from aggregators and channel partners, supporting its role as a growth vector. However, the company cautioned that revenue contributions from this offering will skew later in the year because of standard buying and renewal cycles for smaller employers, limiting its near-term impact on reported top-line growth.</p>
<div class="lb-trans"><p>Progyny Select 繼續受到聚合商和渠道合作伙伴的積極接納和關注，支持其作為增長向量的角色。然而，公司警告稱，由於小型僱主的標準採購和續約週期，該產品的收入貢獻將在年內後期偏向，限制了其對報告的頂線增長的短期影響。</p>
</div><h2>Guidance Highlights and Outlook</h2>
<div class="lb-trans"><h2>指導要點與前景</h2>
</div><p>Looking ahead, Progyny projects second-quarter revenue of $342 million to $355 million and adjusted EBITDA of $58 million to $62 million, with net income of $25.8 million to $28.7 million and GAAP EPS of $0.31 to $0.35. For the full year, management is targeting revenue of $1.365 billion to $1.405 billion, adjusted EBITDA of $232 million to $244 million, and GAAP EPS between $1.23 and $1.34, while assuming stable utilization metrics and steady ART cycle consumption.</p>
<div class="lb-trans"><p>展望未來，Progyny 預計第二季度收入為 3.42 億至 3.55 億美元，調整後的 EBITDA 為 5800 萬至 6200 萬美元，淨收入為 2580 萬至 2870 萬美元，GAAP 每股收益為 0.31 至 0.35 美元。對於全年，管理層的目標是收入為 13.65 億至 14.05 億美元，調整後的 EBITDA 為 2.32 億至 2.44 億美元，GAAP 每股收益在 1.23 至 1.34 美元之間，同時假設利用率指標穩定和 ART 週期消費平穩。</p>
</div><p>Progyny’s earnings call painted a picture of a company balancing investment with discipline, as strong margins, cash flow, and a clean balance sheet offset transition-related headline noise and administrative clean-up work. With raised profitability guidance, robust pipeline activity, and independent validation of its clinical and cost advantages, the firm is positioning itself as a durable growth story in fertility benefits even as it acknowledges and plans for potential volatility in engagement and investor sentiment.</p>
<div class="lb-trans"><p>Progyny 的財報電話會議描繪了一幅公司在投資與紀律之間取得平衡的圖景，強勁的利潤率、現金流和健康的資產負債表抵消了與過渡相關的表面噪音和行政清理工作。隨着盈利指導的上調、強勁的項目活動以及對其臨牀和成本優勢的獨立驗證，該公司正將自己定位為生育福利領域的持久增長故事，即使它承認並計劃應對參與度和投資者情緒的潛在波動。</p>
</div>

Progyny 的財報電話會議傳達了自信且盈利的增長信號